All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the Acute Leukemia Forum (ALF) 2021, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, How should molecular profiling be used to guide MDS therapy?
How should molecular profiling be used to guide MDS therapy?
It is well understood that MDS is caused by somatic mutations in blood cells, influencing a patient's clinical presentation. In this video, Bejar discusses how DNA sequencing can help determine the diagnosis, prognosis, and identify targeted therapy options for patients with a wide variety of MDS risk features and gene mutations.
What is the clinical impact of DDX41 mutations in myeloid neoplasms?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Yasushi Miyazaki, Nagasaki University, Nagasaki, JP. We asked, What is the...
Editorial theme | Immune dysregulation and genetic mutations associated with MDS pathogenesis
The pathogenesis of myelodysplastic syndromes (MDS) is heterogeneous, involving inflammation, cytokines, growth factors, the accumulation of genetic damage,...
Subscribe to get the best content related to MDS delivered to your inbox